Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PBYI | PUMA BIOTECHNOLOGY, INC. | 2025-10-28 15:29:13 | 5.25 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PBYI | 0001401667 | PUMA BIOTECHNOLOGY, INC. | US74587V1070 | — | 770683487 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 10880 WILSHIRE BLVD. | LOS ANGELES | CA | 90024 | UNITED STATES | US | (424) 248-6500 | 10880 WILSHIRE BLVD., LOS ANGELES, CA, 90024 | 10880 WILSHIRE BLVD., LOS ANGELES, CA, 90024 | INNOVATIVE ACQUISITIONS CORP | — | — | — | 265 | http://pumabiotechnology.com | 134,400,000 | 49,892,725 | 50,370,723 | Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA. | 2025-10-23 15:33:01 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 134,400,000 | -7,000,000 | -4.9505 | 49,610,799 | 1,403,637 | 2.9117 |
| 2023 | 141,400,000 | 29,500,000 | 26.3628 | 48,207,162 | 1,565,907 | 3.3573 |
| 2022 | 111,900,000 | -262,000,000 | -70.0722 | 46,641,255 | 5,308,335 | 12.8429 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Alvin Wong | Chief Scientific Officer | 2024 | 413,683 | 0 | 275,433 | 0 | 374,263 | 1,338,769 |
| Jeff J. Ludwig | Chief Commercial Officer | 2024 | 608,499 | 60,850 | 172,146 | 194,355 | 20,320 | 1,228,288 |
| Alan H. Auerbach | Chief Executive Officer, President | 2024 | 904,207 | 0 | 1,055,548 | 938,612 | 16,210 | 3,969,931 |
| Maximo F. Nougues | Chief Financial Officer | 2024 | 538,719 | 123,905 | 275,433 | 172,067 | 19,462 | 1,404,978 |
| Jeff J. Ludwig | Chief Commercial Officer | 2023 | 596,568 | 77,554 | 294,007 | 85,309 | 33,134 | 1,381,848 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 172 |
| 2023 | 185 |
| 2022 | 192 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 230,468,000 | 235,637,000 | 228,031,000 |
| Cost Of Revenue | 64,404,000 | 62,682,000 | 55,093,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 54,935,000 | 50,382,000 | 52,240,000 |
| General And Administrative Expenses | 80,163,000 | 89,933,000 | 89,978,000 |
| Operating Expenses | 199,502,000 | 202,997,000 | 204,311,000 |
| Operating Income | 30,966,000 | 32,640,000 | 23,720,000 |
| Net Income | 30,278,000 | 21,591,000 | 2,000 |
| Earnings Per Share Basic | 0.62 | 0.46 | 0 |
| Earnings Per Share Diluted | 0.62 | 0.45 | 0 |
| Weighted Average Shares Outstanding Basic | 48,648,701 | 47,134,331 | 44,674,501 |
| Weighted Average Shares Outstanding Diluted | 49,100,433 | 47,550,852 | 44,929,998 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 69,219,000 | 84,585,000 | 76,201,000 |
| Marketable Securities Current | 31,746,000 | 11,354,000 | 4,873,000 |
| Accounts Receivable | 32,011,000 | 47,837,000 | 40,350,000 |
| Inventories | 8,724,000 | 7,080,000 | 4,526,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 91,000 | 912,000 | 2,429,000 |
| Total Assets Current | 147,658,000 | 156,185,000 | 134,281,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 515,000 | 855,000 | 1,146,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 65,675,000 | 74,343,000 | 87,778,000 |
| Total Assets | 213,333,000 | 230,528,000 | 222,059,000 |
| Accounts Payable | 5,509,000 | 6,889,000 | 6,440,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 45,329,000 | 33,997,000 | 0 |
| Other Liabilities Current | 36,898,000 | 52,721,000 | 53,034,000 |
| Total Liabilities Current | 96,111,000 | 99,382,000 | 77,484,000 |
| Long Term Debt | 68,003,000 | 102,000,000 | 102,000,000 |
| Other Liabilities Non Current | 121,000 | — | — |
| Total Liabilities Non Current | 25,097,000 | 77,704,000 | 122,967,000 |
| Total Liabilities | 121,208,000 | 177,086,000 | 200,451,000 |
| Common Stock | 5,000 | 5,000 | 5,000 |
| Retained Earnings | -1,314,886,000 | -1,345,164,000 | -1,366,755,000 |
| Accumulated Other Comprehensive Income | 6,000 | -4,000 | 0 |
| Total Shareholders Equity | 92,125,000 | 53,442,000 | 21,608,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 11,524,000 | 11,519,000 | 8,920,000 |
| Share Based Compensation Expense | 8,245,000 | 10,247,000 | 11,826,000 |
| Other Non Cash Income Expense | 0 | 0 | -1,000 |
| Change In Accounts Receivable | -16,345,000 | 8,368,000 | 7,824,000 |
| Change In Inventories | 1,644,000 | 2,554,000 | -2,583,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -1,380,000 | 449,000 | -4,734,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 38,918,000 | 27,009,000 | -15,827,000 |
| Purchases Of Marketable Securities | 76,230,000 | 23,813,000 | 4,836,000 |
| Sales Of Marketable Securities | 55,848,000 | 17,328,000 | 18,940,000 |
| Acquisition Of Property Plant And Equipment | 56,000 | 140,000 | 0 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -20,438,000 | -19,125,000 | 7,104,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 150,000 | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | 0 |
| Cash From Financing Activities | -33,846,000 | 0 | 12,223,000 |
| Change In Cash | -15,366,000 | 7,884,000 | 3,500,000 |
| Cash At End Of Period | 69,219,000 | 84,585,000 | 76,201,000 |
| Income Taxes Paid | 1,218,000 | 737,000 | 384,000 |
| Interest Paid | 10,769,000 | 11,628,000 | 10,319,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 0.62 | 0.46 | 0 |
| Price To Earnings Ratio | 4.9194 | 9.413 | — |
| Earnings Growth Rate | 34.7826 | — | -100 |
| Price Earnings To Growth Ratio | 0.1414 | — | — |
| Book Value Per Share | 1.8937 | 1.1338 | 0.4837 |
| Price To Book Ratio | 1.6106 | 3.8189 | 8.7455 |
| Ebitda | 55,472,000 | 47,177,000 | 20,898,000 |
| Enterprise Value | 192,491,538.05 | 255,503,653.23 | 214,772,139.23 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 1.2302 | 2.5448 | 4.7205 |
| Capital Expenditures | 11,184,000 | 11,228,000 | 8,310,000 |
| Free Cash Flow | 27,734,000 | 15,781,000 | -24,137,000 |
| Return On Equity | 0.3287 | 0.404 | 0.0001 |
| One Year Beta | 1.1227 | 1.3011 | 1.1995 |
| Three Year Beta | 1.1867 | 1.1096 | 1.1275 |
| Five Year Beta | 1.1379 | 1.1759 | 1.1938 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Cesano Alessandra | Director | 2025-07-18 | 27,000 | D | 41,850 |
| AUERBACH ALAN H | Director, President and CEO, 10% owner | 2025-07-09 | 21,580 | D | 7,180,901 |
| HUNT DOUGLAS M | — | 2025-07-09 | 3,443 | D | 164,894 |
| NOUGUES MAXIMO F | Chief Financial Officer | 2025-07-09 | 3,935 | D | 204,229 |
| AUERBACH ALAN H | Director, President and CEO, 10% owner | 2025-07-08 | 25,592 | D | 7,202,481 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| EVERGREEN CAPITAL MANAGEMENT LLC | 2025-09-30 | 509,760 | 96,000 | 5.31 |
| RITHOLTZ WEALTH MANAGEMENT | 2025-09-30 | 2,499,773 | 470,767 | 5.31 |
| Ball & Co Wealth Management Inc. | 2025-09-30 | 16,000 | 3,066 | 5.2185 |
| NISA INVESTMENT ADVISORS, LLC | 2025-09-30 | 1,816 | 342 | 5.3099 |
| Cerity Partners LLC | 2025-09-30 | 54,215 | 10,210 | 5.31 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Fidelity Rutland Square Trust II | 2025-08-31 | Strategic Advisers U.S. Total Stock Fund | FSAKX | 56,600 | 285,264 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 50,850 | 256,284 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 68,471 | 345,093.84 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 28,173 | 141,991.92 | 0.0007 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Extended Market Index Fund | FSMAX | 192,497 | 970,184.88 | 0.0024 |